TORONTO, Sept. 28, 2017 /PRNewswire/ -- Impopharma Inc. ("Impopharma") today announced that it has entered into an assetpurchase, license, and commercialization agreement with Breckenridge Pharmaceutical, Inc. ("Breckenridge").
Under terms of the agreement, Breckenridge has acquired the ANDA, and
"We, along with our partners at Breckenridge, look forward to providing patients a safe, effective and reliable generic version of a leading anti-inflammatory medication," said Theron 'Ted' Odlaug, Ph.D., Impopharma's Executive Chairman. "Impopharma remains committed to its goal of providing patients access to high quality and affordable medicines in differentiated formulations."
"Breckenridge is excited about this opportunity to collaborate with Impopharma to expand our dosage capability and grow our portfolio," said Larry Lapila, President of Breckenridge.
Terms of the transaction were not disclosed. DSF Associates acted as advisor to Impopharma and Life Sciences Legal as Impopharma's legal counsel for this transaction.
Impopharma is a well-resourced development and testing facility with an expert and experienced team located in Concord, Ontario, Canada that specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, dermal products. Please visit www.impopharma.com.
Impopharma Inc.Vien BrewsterVice President, FinanceTel: (905) 760-0232
Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com
Breckenridge Pharmaceutical, Inc. Brian Guy, Vice President – Business Development TEL: 860-828-8140
View original content:http://www.prnewswire.com/news-releases/impopharma-inc-and-breckenridge-pharmaceutical-inc-enter-into-an-asset-purchase-agreement-to-commercialize-the-generic-version-of-a-leading-corticosteroid-product-upon-fda-approval-300527283.html
SOURCE Impopharma Inc.
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All